ERAAs for menopause treatment: Welcome the 'designer estrogens'

Heather D Hirsch; Elim Shih; Holly L Thacker

doi:10.3949/ccjm.84a.15140

ERAAs for menopause treatment: Welcome the 'designer estrogens'

Cleve Clin J Med. 2017 Jun;84(6):463-470. doi: 10.3949/ccjm.84a.15140.

Authors

Heather D Hirsch^{1

2}, Elim Shih³, Holly L Thacker^{4

5}

Affiliations

¹ Assistant Professor, Clinical Internal Medicine, Division of General Internal Medicine, The Ohio State University, Columbus, OH, USA.
² Center for Women's Health, The Ohio State University Wexner Medical Center, Upper Arlington, OH, USA. Heather.Hirsch@osumc.edu.
³ Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, OH, USA.
⁴ Director of Center for Specialized Women's Health, Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

PMID: 28628428
DOI: 10.3949/ccjm.84a.15140

Abstract

Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.

Publication types

Review

MeSH terms

Bone Diseases, Metabolic / drug therapy*
Breast Neoplasms / drug therapy*
Drug Therapy, Combination
Estrogens / pharmacology*
Female
Hot Flashes / drug therapy*
Humans
Menopause / physiology*
Selective Estrogen Receptor Modulators / pharmacology*
Treatment Outcome

Substances

Estrogens
Selective Estrogen Receptor Modulators